BioMarin Pharmaceutical Inc. (BMRN) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reveals several positive elements such as increased revenue guidance and raised EPS projections. However, concerns arise from higher operating expenses, potential competition affecting VOXZOGO, and management's avoidance of specific details in the Q&A session. These mixed signals, combined with uncertainties about competition and market strategy, suggest a neutral sentiment with no clear strong positive or negative trend.
Key Financial Performance
Total Revenue BioMarin reported an 11% year-over-year increase in total revenue for the year-to-date period, driven by strong performance in global enzyme therapies and Skeletal Conditions business units.
Enzyme Therapies Business Unit Revenue The Enzyme Therapies business unit achieved 8% year-to-date growth, although Q3 revenue was flat compared to Q3 2024 due to a higher volume of ALDURAZYME orders in the prior year.
VOXZOGO Revenue VOXZOGO revenue increased 24% year-to-date compared to 2024, with a projected full-year revenue of $900 million to $935 million, representing 25% growth at the midpoint of guidance.
PALYNZIQ Revenue PALYNZIQ revenue grew by more than 20% year-to-date, reflecting increased patient adherence and efficacy.
Operating Cash Flow Operating cash flow reached $369 million in Q3 and $728 million year-to-date, contributing to a total cash and investments balance of approximately $2 billion at the end of Q3.
Non-GAAP Operating Margin Non-GAAP operating margin guidance was updated to 26%-27%, reflecting strong revenue growth and operational execution despite higher R&D and SG&A expenses.
Diluted Earnings Per Share (Non-GAAP) Non-GAAP diluted earnings per share guidance was updated to $3.50-$3.60, incorporating the impact of a $221 million IPR&D charge related to the Inozyme Pharma acquisition.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
VOXZOGO: Achieved 24% year-to-date revenue growth compared to 2024, reaffirmed 2025 revenue outlook of $900 million to $935 million. Expanded to 55 countries and is the standard of care for achondroplasia. Preparing for a second indication for hypochondroplasia with pivotal data expected in 2026.
BMN 333: Next-generation therapy for achondroplasia targeting superior efficacy compared to VOXZOGO. Phase II/III study initiation planned for the first half of 2026.
PALYNZIQ: Achieved over 20% year-to-date revenue growth. Pursuing approval for adolescents aged 12 to 17 in the U.S. and Europe by 2026.
Global Expansion of VOXZOGO: Now available in 55 countries, with 75% of revenue generated outside the U.S. Focused on increasing access and deeper penetration in existing markets.
Hypochondroplasia Market Preparation: Initiatives underway to improve early diagnosis and access globally. Potential launch in 2027 if data supports.
Revenue Growth: Achieved 11% year-to-date total revenue growth compared to 2024. Raised 2025 total revenue guidance to $3.15 billion.
Operational Cash Flow: Generated $728 million year-to-date, contributing to a $2 billion cash and investments balance.
Portfolio Optimization: Discontinuation of multiple research programs and decision to divest ROCTAVIAN to focus on strategic priorities.
Pipeline Development: Advancing multiple indications for VOXZOGO and BMN 333, along with other pipeline assets like BMN 351 and BMN 401.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Hurdles: The company acknowledges that results may differ materially depending on the actions of regulatory authorities, which could impact product approvals and market access.
Strategic Execution Risks: The company has undertaken difficult decisions, including the discontinuation of multiple research programs and the divestment of ROCTAVIAN, which could impact its portfolio and strategic focus.
Market Competition: There is potential competition for VOXZOGO, which could impact revenue projections for 2027 and beyond.
Economic Uncertainties: The company faces uncertainties in revenue projections due to unknown variables over the next two years, which could affect financial performance.
Supply Chain and Operational Challenges: Quarter-to-quarter order timing dynamics and geographical dispersion of patients in the U.S. have created challenges in maintaining consistent revenue growth and patient uptake.
Financial Risks: The company incurred a $221 million charge for acquired in-process research and development, which significantly impacted operating margins and diluted earnings per share in Q3 2025.
Product-Specific Risks: The underdiagnosis of hypochondroplasia and barriers to genetic testing could limit the market potential for VOXZOGO's second indication.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: BioMarin raised the lower end of its full-year 2025 total revenue guidance to $3.15 billion, with the midpoint representing double-digit year-over-year growth. VOXZOGO revenue is expected to reach between $900 million and $935 million for 2025, with Q4 anticipated to be the highest revenue quarter of the year.
Profitability and Earnings: Full-year 2025 non-GAAP operating margin guidance has been updated to 26%-27%, and non-GAAP diluted earnings per share guidance is now between $3.50 and $3.60. The company expects continued strong operating cash flow and profitability growth.
VOXZOGO Expansion: VOXZOGO is expected to maintain strong growth, with global expansion and deeper market penetration. The company is preparing for a potential launch of VOXZOGO for hypochondroplasia in 2027, pending supportive data from a pivotal readout expected in the first half of 2026.
Pipeline Developments: BioMarin is advancing its skeletal conditions portfolio, including VOXZOGO for additional indications and BMN 333, a next-generation therapy for achondroplasia. Phase II/III studies for BMN 333 are expected to begin in the first half of 2026. The company is also pursuing approval of PALYNZIQ for adolescents aged 12-17 in 2026.
2027 Revenue Outlook: BioMarin provided a range of scenarios for 2027 revenue, excluding ROCTAVIAN, with the lower end aligning with current consensus estimates and the higher end potentially reaching $4 billion. However, no specific estimate or narrow range was provided due to uncertainties.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk a little bit more about the scenarios you see for the 2027 guidance and why you are rescinding the guidance now?
A:Brian Mueller explained that the original $4 billion 2027 outlook was reassessed due to factors like potential VOXZOGO competition, the acquisition of Inozyme, and the potential launch of BMN 401 in 2027. They also considered the divestment of ROCTAVIAN. A range of lower and higher case estimates was outlined, with the lower case assuming two competitors successfully launching and taking significant share by 2027, and the higher case assuming significant delays in competition. Despite uncertainties, the lower case estimate aligns with the 2027 consensus.
Q:Do you now have a different appreciation or concern about how much share competition could take, specifically against VOXZOGO?
A:Brian Mueller stated that they have taken a different view based on observed market trends and potential competitor scenarios. The range of outcomes reflects these uncertainties, but it is not a single point-in-time estimate or forecast.
Q:Why were VOXZOGO sales down quarter-over-quarter, and what is the business development strategy?
A:Brian Mueller attributed the slight quarter-over-quarter decline in VOXZOGO sales to timing shifts in specific larger orders and market-by-market forecasts. He reaffirmed the total VOXZOGO range for the year of $900 million to $935 million. Alexander Hardy emphasized that business development is a high priority, with a focus on early-stage collaborations and Phase III pre-commercial and commercial assets. Several deals are in progress.
Q:Can you share qualitative commentary on the prior long-term mid-2030s guidance for VOXZOGO and the anticipated CAGR for the Enzyme Therapies business?
A:Brian Mueller stated that they are targeting high single-digit sustainable growth for enzyme therapies and plan to grow VOXZOGO by deepening patient penetration and expanding indications. However, uncertainties like potential competition make it prudent to avoid taking an official position on a long-term growth rate.
Q:Have you considered share buybacks given the strong cash balance and operating cash flow generation?
A:Alexander Hardy stated that business development is the priority for capital allocation, as it offers the greatest opportunity for incremental growth and stock appreciation. The Board frequently discusses capital allocation strategies.
Q:What specific exposure levels for BMN 333 PK data would give confidence in achieving clinical superiority over VOXZOGO?
A:Gregory Friberg mentioned that they are looking for free CNP levels with at least 3x AUC increases, which were achieved in three different dose levels in the ongoing Phase I study. For annualized growth velocity (AGV) delta over VOXZOGO, they are not ready to comment on a specific number but aim for clinically meaningful differentiation.
Q:What is the 2027 FactSet consensus excluding ROCTAVIAN, and are the longer-term targets like 40% non-GAAP operating margin and $1.25 billion CFO still valid?
A:Brian Mueller clarified that the 2027 FactSet consensus excluding ROCTAVIAN is $3.65 billion. The 40% operating margin target for 2026 remains valid, but the $1.25 billion CFO target for 2027 is top-line dependent and proportional to revenue scenarios.
Q:What should we expect for the 9-milligram cohort in the BMN 351 study, and what is the powering for the hypochondroplasia trial?
A:Gregory Friberg stated that the BMN 351 study will include safety data from the 6, 9, and 12-milligram cohorts, with biopsy results for the 6 and 9-milligram cohorts. The hypochondroplasia trial is powered to measure an AGV delta similar to VOXZOGO in achondroplasia, with confidence in its design.
Q:Can you discuss the contributions of potential commercial competition and the risk of competitors entering the market?
A:Brian Mueller outlined lower case estimates assuming two competitors successfully launching and taking significant share by 2027, and higher case estimates including less competition or successful intellectual property defense. Cristin Hubbard noted that VOXZOGO continues to add patients globally, with slower growth in older U.S. patients but strong adherence rates and a robust life cycle management plan.
Q:What are your thoughts on orphan drug exclusivity for kids under 5 and the potential for patient switching to competitors?
A:Cristin Hubbard stated that most patients satisfied with their current treatment are likely to remain on therapy, irrespective of orphan drug exclusivity. Alexander Hardy mentioned that the FDA petition concerning VOXZOGO's orphan drug exclusivity is in process, with a decision expected at the time of PDUFA.
Q:Why not wait for BridgeBio data before revising the 2027 case estimate, and is the lower end of the range the most conservative scenario?
A:Brian Mueller explained that the range of estimates was shared to address significant investor interest and reflect various scenarios, including potential competition. The lower end is not characterized as the worst-case scenario, nor is the $4 billion the best-case scenario.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numerical details or clear answers in several instances, such as the minimum AGV delta required for BMN 333 to demonstrate clinical superiority over VOXZOGO, the exact long-term growth rate for VOXZOGO, and the specific impact of potential competition on revenue. Additionally, they did not provide a definitive stance on share buybacks or the exact implications of orphan drug exclusivity.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CANOPY
Conditions unit
Enzyme Therapies
Executive VP
Inozyme
Officer Chief
PALYNZIQ date
ROCTAVIAN
Skeletal Conditions
Slide result
TAPP
Therapies unit
VOXZOGO date
VOXZOGO footprint
VOXZOGO outlook
access
age group
basis charge
breakthrough
cash investment
child VOXZOGO
condition unit
development opportunity
end estimate
enzyme therapy
gene therapy
health
hypochondroplasia launch
indication treatment
process
scenario
share basis
standard care
tax
unit indication
variable
BMRN Transcript
BioMarin Pharmaceutical Inc. (BMRN) Q1 2026 Earnings Call Transcript
Positive5-4
BioMarin reported strong financial performance with a 12% revenue increase and a 20% rise in net income, driven by successful product sales. Operating margin improved, indicating operational efficiency. However, regulatory and competitive risks were noted, but these are common in the industry. The absence of clear negative guidance or significant concerns in the Q&A suggests a positive outlook. Despite the lack of market cap data, the financial results and operational improvements are likely to lead to a positive stock price movement in the short term.
BioMarin Pharmaceutical Inc. (BMRN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-11
BioMarin Pharmaceutical Inc. (BMRN) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neutral3-9
BioMarin Pharmaceutical Inc. (BMRN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-4
BMRN Slides
BMRN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
